2023
Deep learning-based groupwise registration for longitudinal MRI analysis in glioma
Hammecher C, van Garderen K, Smits M, Wesseling P, Westerman B, French P, Kouwenhoven M, Verhaak R, Vos F, Bron E, Li B. Deep learning-based groupwise registration for longitudinal MRI analysis in glioma. Proceedings Of The International Society For Magnetic Resonance In Medicine ... Scientific Meeting And Exhibition. 2023 DOI: 10.58530/2023/4361.Peer-Reviewed Original Research
2021
Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer
Kocakavuk E, Anderson K, Varn F, Johnson K, Amin S, Sulman E, Lolkema M, Barthel F, Verhaak R. Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. Nature Genetics 2021, 53: 1088-1096. PMID: 34045764, PMCID: PMC8483261, DOI: 10.1038/s41588-021-00874-3.Peer-Reviewed Original ResearchConceptsWorse clinical outcomesNon-irradiated tumorsClinical outcomesRecurrent cancerPatient survivalPoor outcomeMetastatic tumorsRecurrent gliomaRadiation therapyRadiation-induced DNA damageDNA damageGlioma Longitudinal Analysis ConsortiumMutational signature analysisCancer treatmentDeletion burdenRadiotherapyMedical FoundationAPOBEC mutagenesisSignificant increaseTumorsCancerDNA damage repairDeletion signatureMutational spectrumSmall deletions
2019
GENE-28. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS
Barthel F, Johnson K, Varn F, Moskalik A, Tanner G, Kocakavuk E, Anderson K, Abiola O, Consortium G, Huse J, DeGroot J, Stead L, Verhaak R. GENE-28. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS. Neuro-Oncology 2019, 21: vi103-vi103. PMCID: PMC6847692, DOI: 10.1093/neuonc/noz175.430.Peer-Reviewed Original ResearchAdult patientsOverall survivalDisease recurrencePoor outcomeCurrent therapiesInitial diseaseTreatment optionsTherapy resistanceNeoantigen profilesTherapeutic interventionsPatientsPathway alterationsTumor progressionGlioma Longitudinal Analysis ConsortiumTargeted inhibitorsCancer typesGlioma developmentGliomasDiffuse gliomasGlioma subtypesTime pointsUnderstanding of mechanismsRecurrenceGlioma datasetsHypermutator phenotype